Hormone FDA Approved

Octreotide

A somatostatin analog widely used in endocrine and neuroendocrine medicine, and one of the most important approved peptide drugs missing from many peptide libraries.

Somatostatin AnalogFDA ApprovedEndocrineNeuroendocrine

Also referenced as: Sandostatin, Sandostatin LAR

Status
FDA Approved

This peptide maps to at least one regulated medical product or label context in the United States.

Category
Hormone

This profile is grouped by its dominant research and market lane, not by vendor shelf placement.

Aliases
2

Sandostatin, Sandostatin LAR

Signal depth
High

FDA label signal · 377 trials · 9612 PubMed results

Established
Research evidence

Octreotide is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.

Octreotide has 49 name-matched clinical trials (3 international) (highest phase: Phase 4) and 9612 PubMed-indexed publications and holds an FDA drug label. 6 trials have posted results.

🌍 3 international trials FAERS (approved drug): 7,832
Human data
Approved drug
Trial quality
Large RCT
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
Top-tier journals
PHASE4 · Randomized Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial) PHASE4 · Randomized Pegvisomant And Sandostatin LAR Combination Study PHASE4 · Randomized Preoperative Octreotide Treatment of Acromegaly ISRCTN A feasibility study of octreotide infusion during liver transplant ISRCTN A clinical study to compare the performance of a novel solid dose injection of octreotide with a reference product Journal of Clinical Oncology · 2,502 citations Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What octreotide is

Octreotide is a somatostatin analog used in regulated medicine for multiple endocrine and neuroendocrine indications.

Why it matters

It is one of the foundational approved peptide drugs and helps anchor the library in real peptide pharmacology beyond research-market compounds.

Regulatory context

Octreotide is FDA approved in the United States and exists in both immediate-release and long-acting forms.

Practical reading note

Octreotide is a reminder that some of the most important peptides in medicine are not trendy at all. They are just deeply established.